1. Technology overview
Therapixel is a French medical imaging AI company set up in 2013 by Olivier Clatz and Pierre Fillard, with headquarters at 455 Promenade des Anglais in Nice and research teams in Paris. It refocused entirely on radiology after selling its surgical products unit in June 2020.
Its product MammoScreen is an AI tool for interpreting screening mammograms and enables breast cancer detection at first reading. It is FDA cleared, including 3D mammography (digital breast tomosynthesis), and CE marked. The company won the DREAM Digital Mammography Challenge in 2017 and its investors include Creazur, Omnes and M Capital.
2. Highlighted features & specifications
- MammoScreen 2D/3D: AI interpretation of digital mammography and tomosynthesis.
- First-reading detection: flags suspicious findings at the initial read.
- Prior exam comparison: a version that leverages prior exams for better accuracy.
- FDA 510(k) clearance for 3D mammography, granted in November 2021.
- Partner deployment: offered through provider networks such as Onsite Women's Health.
- Clinical evidence: prospective French study on AI as second reading in screening.
3. Potential application
Private hospital groups in Vietnam could use MammoScreen as a second reader for screening mammograms. Women's health clinics could prioritize suspicious cases for radiologist review. Breast imaging centers could use it for quality control audits.
4. Benefits
Supports radiologists with AI-assisted reading of 2D and 3D mammograms.
The company reports detection of 42% of cancers one year before diagnosis and 38.5% two years before, as company-reported figures.
FDA cleared and CE marked, easing deployment in the US and Europe.
Used at large providers, including Mayo Clinic and the Onsite Women's Health network of 150+ locations (per Therapixel news).
5. Market trends & opportunities
Breast cancer screening programs are adding AI as a second reader to ease radiologist shortages. Vietnam is expanding mammography use in private hospitals and women's health clinics. Procurement increasingly favors tools with both FDA and CE status.
6. Other information
Founded 2013; headquarters at 455 Promenade des Anglais, 06200 Nice, France. Investors include Creazur, IT Translation, Omnes, M Capital and Region Sud Investissement. Mayo Clinic selection dated June 2025 and Onsite Women's Health partnership April 2025.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































